Ga-68-labeled somatostatin analogs are important imaging agents to detect and manage neuroendocrine tumors (NETs). The SNMMI formed the 68Ga Users Group to advance the use of these imaging agents in the US. Members of the Users Group developed harmonized release criteria, an imaging manual, generic data collection forms and a draft informed consent form to aid the community in establishing investigator-sponsored trials. In October 2013, the Society of Nuclear Medicine and Molecular Imaging (SNMMI) received orphan drug designation for Ga-68 DOTATOC.

Click hereto see the slides from the Gallium Information Session held in St. Louis during the SNMMI Annual Meeting on June 9th, 2014.

PRRTInfor.org continues to support the work of the 68Ga Users Group.   One of the orginators of this site, Josh Mailman has been a member of the working group which meets monthly since January 2012.